Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease

Zhang, Xiaochen; Ishikawa, Dai; Ohkusa, Toshifumi; Fukuda, Shinji; Nagahara, Akihito

doi:10.3389/fmed.2022.1068567

Cited by 9 publications

(5 citation statements)

References 121 publications

(159 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FMT has been demonstrated to restore altered microbiota and reconstruct the gut micro ecosystem and modulate both the innate and adaptive arms of the immune systed, leading to therapeutic outcomes for different diseases [186]. Among these, it has been very successful and extensively used for treating Clostridioides difficile infection implicated in IBD [187].…”

Section: Fecal Microbiota Transplants As Therapymentioning

confidence: 99%

Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach

Tan,

Akelew,

Snelson

et al. 2024

Preprint

View full text Add to dashboard Cite

Autoimmune kidney diseases arise from a loss of tolerance to antigens, often with unclear triggers. In this review we explore the role of the gut microbiome and how disease, diet and therapy can alter the gut microbiota consortium. Perturbations in the gut microbiota may induce the translocation of microbiota-derived inflammatory molecules such as liposaccharide (LPS) and other toxins systemically by penetrating the gut epithelial barrier. Once in the blood stream these pro-inflammatory mediators activate immune cells which release pro-inflammatory molecules many of which are antigens in autoimmune diseases. The ratio of gut bacteria Bacteroidetes:Firmicutes is associated with worse outcomes in multiple autoimmune kidney diseases including Lupus nephritis, MPO-ANCA vasculitis and Goodpasture’s syndrome. Therapies which enhance short chain fatty acid (SCFA)-producing bacteria in the gut have powerful therapeutic potential. Dietary fibre is fermented by gut bacteria which in turn release SCFAs which protect the gut barrier as well as modulate immune responses towards a tolerogenic anti-inflammatory state. Herein, we describe where the current field of research is and the strategies to harness the gut microbiome as potential therapy.

show abstract

Section: Fecal Microbiota Transplants As Therapymentioning

confidence: 99%

Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach

Tan,

Akelew,

Snelson

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…FMT has been demonstrated to restore altered microbiota, reconstruct the gut micro-ecosystem, and modulate both the innate and adaptive arms of the immune system, leading to therapeutic outcomes for different diseases [175]. Among these, it has been very successful and extensively used for treating Clostridioides difficile infection implicated in IBD [176].…”

Section: Fecal Microbiota Transplants As Therapymentioning

confidence: 99%

Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach

Tan,

Akelew,

Snelson

et al. 2024

IJMS

View full text Add to dashboard Cite

The gut microbiota and short chain fatty acids (SCFA) have been associated with immune regulation and autoimmune diseases. Autoimmune kidney diseases arise from a loss of tolerance to antigens, often with unclear triggers. In this review, we explore the role of the gut microbiome and how disease, diet, and therapy can alter the gut microbiota consortium. Perturbations in the gut microbiota may systemically induce the translocation of microbiota-derived inflammatory molecules such as liposaccharide (LPS) and other toxins by penetrating the gut epithelial barrier. Once in the blood stream, these pro-inflammatory mediators activate immune cells, which release pro-inflammatory molecules, many of which are antigens in autoimmune diseases. The ratio of gut bacteria Bacteroidetes/Firmicutes is associated with worse outcomes in multiple autoimmune kidney diseases including lupus nephritis, MPO-ANCA vasculitis, and Goodpasture’s syndrome. Therapies that enhance SCFA-producing bacteria in the gut have powerful therapeutic potential. Dietary fiber is fermented by gut bacteria which in turn release SCFAs that protect the gut barrier, as well as modulating immune responses towards a tolerogenic anti-inflammatory state. Herein, we describe where the current field of research is and the strategies to harness the gut microbiome as potential therapy.

show abstract

“…The use of FMT has been prevalent in cases of Clostridium difficile infection (CDI) and IBD [149]. Comparing the GI tracts, microbial abundance, and diversity between IBD patients and healthy individuals showed a significant difference [150].…”

Section: Fecal Microbiota Transplantation (Fmt)mentioning

confidence: 99%

Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer’s Disease

Muraleedharan,

Ray

2024

Brain Sciences

View full text Add to dashboard Cite

There are approximately 24 million cases of Alzheimer’s disease (AD) worldwide, and the number of cases is expected to increase four-fold by 2050. AD is a neurodegenerative disease that leads to severe dementia in most patients. There are several neuropathological signs of AD, such as deposition of amyloid beta (Aβ) plaques, formation of neurofibrillary tangles (NFTs), neuronal loss, activation of inflammasomes, and declining autophagy. Several of these hallmarks are linked to the gut microbiome. The gastrointestinal (GI) tract contains microbial diversity, which is important in regulating several functions in the brain via the gut-brain axis (GBA). The disruption of the balance in the gut microbiota is known as gut dysbiosis. Recent studies strongly support that targeting gut dysbiosis with selective bioflavonoids is a highly plausible solution to attenuate activation of inflammasomes (contributing to neuroinflammation) and resume autophagy (a cellular mechanism for lysosomal degradation of the damaged components and recycling of building blocks) to stop AD pathogenesis. This review is focused on two bioflavonoids, specifically epigallocatechin-3-gallate (EGCG) and genistein (GS), as a possible new paradigm of treatment for maintaining healthy gut microbiota in AD due to their implications in modulating crucial AD signaling pathways. The combination of EGCG and GS has a higher potential than either agent alone to attenuate the signaling pathways implicated in AD pathogenesis. The effects of EGCG and GS on altering gut microbiota and GBA were also explored, along with conclusions from various delivery methods to increase the bioavailability of these bioflavonoids in the body.

show abstract

Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease

Cited by 9 publications

References 121 publications

Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach

Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach

Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach

Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer’s Disease

Contact Info

Product

Resources

About